Portal de Periódicos da CAPES

Use of Total Lymphocyte Count for Monitoring Response to Antiretroviral Therapy

2004; Oxford University Press; Volume: 38; Issue: 2 Linguagem: Inglês

10.1086/380792

1537-6591

Tanya Schreibman, Gerald Friedland,

HIV-related health complications and treatments

The CD4 cell count has become a key laboratory measurement in the management of human immunodeficiency virus (HIV) disease. In ideal situations, HIV-infected persons are followed up longitudinally with serial CD4 cell counts to determine disease progression, risk for opportunistic infection, and the need for prophylactic or therapeutic intervention. However, the use of the CD4 cell count in resource-limited settings is often not possible because of lack of availability and high cost. Thus, other laboratory markers have been proposed as substitutes for the CD4 cell count. The data regarding the clinical utility of the total lymphocyte count (TLC) as a potential surrogate marker of immune function in patients with HIV disease are examined. The role of the TLC in the initiation of antiretroviral therapy and opportunistic infection prophylaxis, as well as the role of the TLC in monitoring the response to antiretroviral therapy, are also addressed.